The accuracy, response speed, cost, and size are important determinants of the performance of a Continuous Glucose Monitoring (CGM) system. Current CGM systems either require (i) percutaneous wires with bulky skin-worn transmitters, frequent removal/insertion, and thousands of dollars, or (ii) bulky implants, special semi-surgical procedures, and frequent recalibrations. By integrating modern semiconductor and nano technologies, IMS invented miniaturized (0.1mmx0.6mmx3mm i.e., smaller than a sesame seed) fully wireless, minimally invasive subdermal CGM platform. The sensor is user-insertable under the skin using an injector and is also user-removable. It is powered via an external smartwatch transmitter using standard RFID technology. This enables low power RF communication with the transmitter. The transmitter uses a bluetooth low-energy link to send the data to a smartphone reader enabling machine-learning based decision support.

IMS has verified the system through extensive in-vitro and in-vivo testing; the latest test for more than 1 month in a porcine model (Figure 1). The sensor shows fast response speed, best-in-class accuracy, and highly biocompatible operation due to use of standard materials and small size. We are currently working to get FDA IDE for first-in-human study.

Figure 1. Sensor Performance Results (a) using FDA iCGM (b) Clarke Error Grid.


M. Mujeeb-U-Rahman: None. M. Honarvar Nazari: None. M. Sencan: Employee; Self; Integrated Medical Sensors.


National Institutes of Health (DK109811, DK111001)

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at